VivoSeq
Other

Lorlatinib

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Lorlatinib is an early-stage landscape with 0 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed5 · 50%
Active, not recruiting3 · 30%
Unknown status1 · 10%
Approved for marketing1 · 10%

Clinical Trials

Trial Activity

10 trials

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Active, not recruiting·Pfizer logoPfizer·Phase 3·NCT03052608·296 enrolled
Lorlatinib Continuation Study
Active, not recruiting·Pfizer logoPfizer·Phase 4·NCT05144997·76 enrolled
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
Active, not recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT04621188·54 enrolled
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
Completed·Pfizer logoPfizer·Phase 1·NCT05224609·21 enrolled
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
Completed·Pfizer logoPfizer·N/A·NCT04979988·51 enrolled
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
Completed·Pfizer logoPfizer·Phase 1·NCT03184168·6 enrolled
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Completed·Pfizer logoPfizer·Phase 2·NCT03909971·109 enrolled
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT03107988·65 enrolled
Study of Lorlatinib in ROS1 Rearranged NSCLC
Unknown status·National Cancer Center, Korea·Phase 2·NCT03612154·35 enrolled
Lorlatinib - PF-06463922
Approved for marketing·Pfizer logoPfizer·N/A·NCT03127618

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)